XTER:EVT (Germany)
Business Description
Evotec SE
NAICS : 325412
SIC : 2834
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Compare
Compare
Traded in other countries / regions
EVT.Austria
•
EVTA.Germany
•
EVT.Switzerland
•
0IRF.UK
•
EVOTF.USA
Description
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.65 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.4 | |||||
| Debt-to-EBITDA | 4.15 | |||||
| Interest Coverage | 3.19 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.74 | |||||
| Beneish M-Score | -2.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.4 | |||||
| 3-Year EBITDA Growth Rate | 38 | |||||
| 3-Year EPS without NRI Growth Rate | 32.4 | |||||
| 3-Year FCF Growth Rate | -71.6 | |||||
| 3-Year Book Growth Rate | 39.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 19.01 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.78 | |||||
| 9-Day RSI | 40.51 | |||||
| 14-Day RSI | 45.59 | |||||
| 6-1 Month Momentum % | -10.73 | |||||
| 12-1 Month Momentum % | -35.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.13 | |||||
| Quick Ratio | 3.05 | |||||
| Cash Ratio | 2.52 | |||||
| Days Inventory | 15.72 | |||||
| Days Sales Outstanding | 57.44 | |||||
| Days Payable | 45.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.9 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 23.58 | |||||
| Operating Margin % | 5.44 | |||||
| Net Margin % | 13.79 | |||||
| ROE % | 8.41 | |||||
| ROA % | 4.77 | |||||
| ROIC % | 2.19 | |||||
| ROC (Joel Greenblatt) % | 27.11 | |||||
| ROCE % | 7.82 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 43.97 | |||||
| PE Ratio without NRI | 43.64 | |||||
| Shiller PE Ratio | 112.18 | |||||
| Price-to-Owner-Earnings | 45.36 | |||||
| PEG Ratio | 1.29 | |||||
| PS Ratio | 6.67 | |||||
| PB Ratio | 3.45 | |||||
| Price-to-Tangible-Book | 4.38 | |||||
| Price-to-Free-Cash-Flow | 77.05 | |||||
| Price-to-Operating-Cash-Flow | 23.83 | |||||
| EV-to-EBIT | 33.17 | |||||
| EV-to-EBITDA | 33.17 | |||||
| EV-to-Revenue | 6.37 | |||||
| EV-to-Forward-Revenue | 5.59 | |||||
| EV-to-FCF | 71.05 | |||||
| Price-to-Projected-FCF | 3.14 | |||||
| Price-to-Median-PS-Value | 0.99 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.75 | |||||
| Price-to-Graham-Number | 2.91 | |||||
| Price-to-Net-Current-Asset-Value | 24.1 | |||||
| Earnings Yield (Greenblatt) % | 3.02 | |||||
| Forward Rate of Return (Yacktman) % | 20.5 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 649.621 | ||
| EPS (TTM) (€) | 0.58 | ||
| Beta | 0.77 | ||
| Volatility % | 45.12 | ||
| 14-Day RSI | 45.59 | ||
| 14-Day ATR (€) | 1.22971 | ||
| 20-Day SMA (€) | 26.254 | ||
| 12-1 Month Momentum % | -35.16 | ||
| 52-Week Range (€) | 20.16 - 45.83 | ||
| Shares Outstanding (Mil) | 176.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evotec SE Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||